Price Target Update on Pacific Biosciences of California (NASDAQ:PACB)

Pacific Biosciences of California (NASDAQ:PACB) stock is expected to deviate a maximum of $4.24 from the average target price of $12 for the short term period. 4 Street Experts have initiated coverage on the stock with the most promising target being $18 and the most muted being $8.

Other Equity analysts have also commented on the company shares. MKM Partners initiates coverage on Pacific Biosciences of California (NASDAQ:PACB) The brokerage firm has issued a Neutral rating on the shares. The Analysts at the ratings agency announces the price target to $16.5 per share. The rating by the firm was issued on April 15, 2016.

Pacific Biosciences of California (NASDAQ:PACB): On Thursdays trading session , Opening price of the stock was $8.88 with an intraday high of $9.06. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $8.33. However, the stock managed to close at $8.6, a loss of 2.16% for the day. On the previous day, the stock had closed at $8.79. The total traded volume of the day was 2,972,764 shares.

The company shares have rallied 68.07% from its 1 Year high price. On Dec 31, 2015, the shares registered one year high at $14.00 and the one year low was seen on Sep 30, 2015. The 50-Day Moving Average price is $9.19 and the 200 Day Moving Average price is recorded at $9.81. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Phillips James Michael, officer (SVP, Research & Development) of Pacific Biosciences Of California, Inc., had unloaded 20,000 shares at an average price of $10.29 in a transaction dated on April 25, 2016. The total value of the transaction was worth $205,800.

Pacific Biosciences of California Inc. designs, develops and manufactures the PacBio RS II Sequencing System to help scientists resolve genetically complex problems. Based on the Companys Single Molecule, Real-Time (SMRT) technology, its products enable de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA (deoxyribonucleic acid) base modification identification to help characterize epigenetic regulation and DNA damage. SMRT enables single molecule, real-time detection of biological processes. Based on its SMRT technology, the Company introduced the PacBio RS II System to address many of the limitations.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.